{
    "id": 108,
    "premise": "none",
    "hypothesis": "Patient may benefit from treatment with Trastuzumab",
    "label": "entailment",
    "explanation": "With the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, the prognosis for HER2+ breast cancer patients has dramatically improved.\nPatient has V777L HER 2 mutated and HER 2 amplified breast cancer.",
    "results": {
        "semantic validity": true,
        "premise": null,
        "hypothesis": "Patient may benefit from treatment with Trastuzumab",
        "refined explanation": "With the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, the prognosis for HER2+ breast cancer patients has dramatically improved.\nPatient has V777L HER2 mutated and HER2 amplified breast cancer.\nPatients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab.",
        "refined iteration": 1,
        "history explanation": [
            "0 iteration: With the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, the prognosis for HER2+ breast cancer patients has dramatically improved.\nPatient has V777L HER 2 mutated and HER 2 amplified breast cancer.",
            "1 iteration: With the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, the prognosis for HER2+ breast cancer patients has dramatically improved.\nPatient has V777L HER2 mutated and HER2 amplified breast cancer.\nPatients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab."
        ],
        "history semantic validity": [
            "0 iteration: False",
            "1 iteration: True"
        ],
        "history critique output": [
            "0 iteration: {'syntactic validity': True, 'error code': '(* Explanation 1 provides a logical relation Implies(A, B), which implies that the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, leads to improved prognosis for HER2+ breast cancer patients. *)\\n(* Explanation 2 indicates that the patient has V777L HER2 mutated and HER2 amplified breast cancer. *)\\n(* From the derived implications, we have Implies(A, D), which means the development of trastuzumab implies the patient has HER2 amplified breast cancer. *)\\n(* Since the patient has HER2 amplified breast cancer, they may benefit from treatment with Trastuzumab. *)\\nthen have \"Benefit e \u2227 Agent e x \u2227 Source e y\" sledgehammer', 'solving time': 104.95651888847351, 'proof tactics': [], 'code': 'theory clinical_108_0\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Prognosis :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  HER2Positive :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  Antibody :: \"entity \u21d2 bool\"\\n  Humanized :: \"entity \u21d2 bool\"\\n  Monoclonal :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  HER2Receptor :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Development :: \"event \u21d2 bool\"\\n  Means :: \"event \u21d2 entity \u21d2 bool\"\\n  Improved :: \"event \u21d2 bool\"\\n  Dramatically :: \"event \u21d2 bool\"\\n  V777L :: \"entity \u21d2 bool\"\\n  HER2Mutated :: \"entity \u21d2 bool\"\\n  HER2Amplified :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Source :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: With the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, the prognosis for HER2+ breast cancer patients has dramatically improved. *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Prognosis x \u2227 Patient y \u2227 HER2Positive y \u2227 BreastCancer y \u2227 Antibody z \u2227 Humanized z \u2227 Monoclonal z \u2227 Target e1 \u2227 HER2Receptor e1 \u2227 Agent e1 z \u2227 Trastuzumab z \u2227 Development e2 \u2227 Means e2 z \u2227 Improved e2 \u2227 Agent e2 y \u2227 Dramatically e2\"\\n\\n(* Explanation 2: Patient has V777L HER 2 mutated and HER 2 amplified breast cancer. *)\\naxiomatization where\\n  explanation_2: \"\u2203x y z. Patient x \u2227 BreastCancer y \u2227 V777L y \u2227 HER2Mutated y \u2227 HER2Amplified y \u2227 Has x y\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Trastuzumab y\"\\n  (* Hypothesis: Patient may benefit from treatment with Trastuzumab. *)\\n  shows \"\u2203x y e. Patient x \u2227 Treatment y \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 Source e y\"\\nproof -\\n  (* From the premise, we have known information about the patient and treatment with Trastuzumab. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Trastuzumab y\" <ATP>\\n  (* Explanation 1 provides a logical relation Implies(A, B), which implies that the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, leads to improved prognosis for HER2+ breast cancer patients. *)\\n  (* Explanation 2 indicates that the patient has V777L HER2 mutated and HER2 amplified breast cancer. *)\\n  (* From the derived implications, we have Implies(A, D), which means the development of trastuzumab implies the patient has HER2 amplified breast cancer. *)\\n  (* Since the patient has HER2 amplified breast cancer, they may benefit from treatment with Trastuzumab. *)\\n  then have \"Benefit e \u2227 Agent e x \u2227 Source e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab (from Explanatory Sentence 1)\\nB: prognosis for HER2+ breast cancer patients has dramatically improved (from Explanatory Sentence 1)\\nC: patient has V777L HER2 mutated breast cancer (from Explanatory Sentence 2)\\nD: patient has HER2 amplified breast cancer (from Explanatory Sentence 2)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, prognosis for HER2+ breast cancer patients has dramatically improved)\\n--------\\nAnd(C, D)\\nC & D\\n--------\\n\\nDerived Implications:\\nImplies(Not(A), C)\\nImplies(Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab), patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(C), C)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(patient has HER2 amplified breast cancer), Not(prognosis for HER2+ breast cancer patients has dramatically improved))\\n--------\\nImplies(Not(D), D)\\nImplies(Not(patient has HER2 amplified breast cancer), patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(patient has HER2 amplified breast cancer), Not(patient has V777L HER2 mutated breast cancer))\\n--------\\nImplies(Not(C), Not(B))\\nImplies(Not(patient has V777L HER2 mutated breast cancer), Not(prognosis for HER2+ breast cancer patients has dramatically improved))\\n--------\\nImplies(Not(A), D)\\nImplies(Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab), patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(D), B)\\nImplies(Not(patient has HER2 amplified breast cancer), prognosis for HER2+ breast cancer patients has dramatically improved)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(patient has HER2 amplified breast cancer), Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient has V777L HER2 mutated breast cancer), Not(patient has HER2 amplified breast cancer))\\n--------\\nImplies(Not(C), B)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), prognosis for HER2+ breast cancer patients has dramatically improved)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient has V777L HER2 mutated breast cancer), Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab))\\n--------\\nImplies(C, D)\\nImplies(patient has V777L HER2 mutated breast cancer, patient has HER2 amplified breast cancer)\\n--------\\nImplies(B, C)\\nImplies(prognosis for HER2+ breast cancer patients has dramatically improved, patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(A, C)\\nImplies(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(D), A)\\nImplies(Not(patient has HER2 amplified breast cancer), development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab)\\n--------\\nImplies(B, D)\\nImplies(prognosis for HER2+ breast cancer patients has dramatically improved, patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(C), A)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab)\\n--------\\nImplies(A, D)\\nImplies(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(prognosis for HER2+ breast cancer patients has dramatically improved), patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(prognosis for HER2+ breast cancer patients has dramatically improved), patient has HER2 amplified breast cancer)\\n--------\\nImplies(D, C)\\nImplies(patient has HER2 amplified breast cancer, patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(D), C)\\nImplies(Not(patient has HER2 amplified breast cancer), patient has V777L HER2 mutated breast cancer)\\n--------\\n'}",
            "1 iteration: {'syntactic validity': True, 'error code': '', 'solving time': 10.52717900276184, 'proof tactics': ['Sledgehammering...', 'zipperposition found a proof...', 'cvc4 found a proof...', 'verit found a proof...', 'vampire found a proof...', 'verit: Try this: using explanation_3 by blast (1 ms)', 'cvc4 found a proof...', 'cvc4: Found duplicate proof', 'zipperposition: Found duplicate proof', 'e found a proof...', 'e: Found duplicate proof', 'cvc4: Found duplicate proof', 'vampire: Found duplicate proof', 'Done'], 'code': 'theory clinical_108_1\\nimports Main\\n\\nbegin\\n\\ntypedecl entity\\ntypedecl event\\n\\nconsts\\n  Prognosis :: \"entity \u21d2 bool\"\\n  Patient :: \"entity \u21d2 bool\"\\n  HER2Positive :: \"entity \u21d2 bool\"\\n  BreastCancer :: \"entity \u21d2 bool\"\\n  Antibody :: \"entity \u21d2 bool\"\\n  Humanized :: \"entity \u21d2 bool\"\\n  Monoclonal :: \"entity \u21d2 bool\"\\n  Target :: \"event \u21d2 bool\"\\n  HER2Receptor :: \"event \u21d2 bool\"\\n  Agent :: \"event \u21d2 entity \u21d2 bool\"\\n  Trastuzumab :: \"entity \u21d2 bool\"\\n  Development :: \"event \u21d2 bool\"\\n  Means :: \"event \u21d2 entity \u21d2 bool\"\\n  Improved :: \"event \u21d2 bool\"\\n  Dramatically :: \"event \u21d2 bool\"\\n  V777LHER2Mutated :: \"entity \u21d2 bool\"\\n  HER2Amplified :: \"entity \u21d2 bool\"\\n  Has :: \"entity \u21d2 entity \u21d2 bool\"\\n  Treatment :: \"entity \u21d2 bool\"\\n  Benefit :: \"event \u21d2 bool\"\\n  Source :: \"event \u21d2 entity \u21d2 bool\"\\n\\n(* Explanation 1: With the development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, the prognosis for HER2+ breast cancer patients has dramatically improved *)\\naxiomatization where\\n  explanation_1: \"\u2203x y z e1 e2. Prognosis x \u2227 Patient y \u2227 HER2Positive y \u2227 BreastCancer y \u2227 Antibody z \u2227 Humanized z \u2227 Monoclonal z \u2227 Target e1 \u2227 HER2Receptor e1 \u2227 Agent e1 z \u2227 Trastuzumab z \u2227 Development e2 \u2227 Means e2 z \u2227 Improved e2 \u2227 Agent e2 x \u2227 Dramatically e2\"\\n\\n(* Explanation 2: Patient has V777L HER2 mutated and HER2 amplified breast cancer *)\\naxiomatization where\\n  explanation_2: \"\u2203x y. Patient x \u2227 BreastCancer y \u2227 V777LHER2Mutated y \u2227 HER2Amplified y \u2227 Has x y\"\\n\\n(* Explanation 3: Patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab *)\\naxiomatization where\\n  explanation_3: \"\u2203x y z e. Patient x \u2227 BreastCancer y \u2227 HER2Amplified y \u2227 Treatment z \u2227 Trastuzumab z \u2227 Benefit e \u2227 Agent e x \u2227 Source e z\"\\n\\ntheorem hypothesis:\\n  assumes asm: \"Patient x \u2227 Treatment y \u2227 Trastuzumab y\"\\n  (* Hypothesis: Patient may benefit from treatment with Trastuzumab *)\\n  shows \"\u2203x y e. Patient x \u2227 Treatment y \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 Source e y\"\\nproof -\\n  (* From the premise, we have known information about the patient and treatment with Trastuzumab. *)\\n  from asm have \"Patient x \u2227 Treatment y \u2227 Trastuzumab y\" <ATP>\\n  (* Explanation 3 states that patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab. *)\\n  (* There is a logical relation Implies(D, E), Implies(patient has HER2 amplified breast cancer, patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab). *)\\n  (* From Explanation 2, we know that if a patient has V777L HER2 mutated breast cancer, they also have HER2 amplified breast cancer. *)\\n  (* Therefore, we can infer that the patient may benefit from treatment with Trastuzumab. *)\\n  then have \"\u2203x y e. Patient x \u2227 Treatment y \u2227 Trastuzumab y \u2227 Benefit e \u2227 Agent e x \u2227 Source e y\" <ATP>\\n  then show ?thesis <ATP>\\nqed\\n\\nend\\n', 'logical information': 'Logical Propositions:\\nA: development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab (from Explanatory Sentence 1)\\nB: prognosis for HER2+ breast cancer patients has dramatically improved (from Explanatory Sentence 1)\\nC: patient has V777L HER2 mutated breast cancer (from Explanatory Sentence 2)\\nD: patient has HER2 amplified breast cancer (from Explanatory Sentence 2)\\nE: patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab (from Explanatory Sentence 3)\\n\\nLogical Relations:\\nImplies(A, B)\\nImplies(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, prognosis for HER2+ breast cancer patients has dramatically improved)\\n--------\\nAnd(C, D)\\nC & D\\n--------\\nImplies(D, E)\\nImplies(patient has HER2 amplified breast cancer, patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\n\\nDerived Implications:\\nImplies(B, E)\\nImplies(prognosis for HER2+ breast cancer patients has dramatically improved, patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), C)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(A), C)\\nImplies(Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab), patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(D), Not(B))\\nImplies(Not(patient has HER2 amplified breast cancer), Not(prognosis for HER2+ breast cancer patients has dramatically improved))\\n--------\\nImplies(A, E)\\nImplies(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(D), Not(E))\\nImplies(Not(patient has HER2 amplified breast cancer), Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab))\\n--------\\nImplies(Not(D), D)\\nImplies(Not(patient has HER2 amplified breast cancer), patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(D), Not(C))\\nImplies(Not(patient has HER2 amplified breast cancer), Not(patient has V777L HER2 mutated breast cancer))\\n--------\\nImplies(Not(C), Not(B))\\nImplies(Not(patient has V777L HER2 mutated breast cancer), Not(prognosis for HER2+ breast cancer patients has dramatically improved))\\n--------\\nImplies(Not(A), D)\\nImplies(Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab), patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(C), D)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(D), B)\\nImplies(Not(patient has HER2 amplified breast cancer), prognosis for HER2+ breast cancer patients has dramatically improved)\\n--------\\nImplies(Not(D), Not(A))\\nImplies(Not(patient has HER2 amplified breast cancer), Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab))\\n--------\\nImplies(Not(B), E)\\nImplies(Not(prognosis for HER2+ breast cancer patients has dramatically improved), patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), Not(E))\\nImplies(Not(patient has V777L HER2 mutated breast cancer), Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab))\\n--------\\nImplies(Not(C), Not(D))\\nImplies(Not(patient has V777L HER2 mutated breast cancer), Not(patient has HER2 amplified breast cancer))\\n--------\\nImplies(Not(C), B)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), prognosis for HER2+ breast cancer patients has dramatically improved)\\n--------\\nImplies(Not(C), Not(A))\\nImplies(Not(patient has V777L HER2 mutated breast cancer), Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab))\\n--------\\nImplies(Not(E), C)\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(C, D)\\nImplies(patient has V777L HER2 mutated breast cancer, patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(E), Not(B))\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), Not(prognosis for HER2+ breast cancer patients has dramatically improved))\\n--------\\nImplies(B, C)\\nImplies(prognosis for HER2+ breast cancer patients has dramatically improved, patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(E), D)\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), patient has HER2 amplified breast cancer)\\n--------\\nImplies(A, C)\\nImplies(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(E), B)\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), prognosis for HER2+ breast cancer patients has dramatically improved)\\n--------\\nImplies(Not(E), Not(C))\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), Not(patient has V777L HER2 mutated breast cancer))\\n--------\\nImplies(Not(E), Not(A))\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab))\\n--------\\nImplies(Not(D), A)\\nImplies(Not(patient has HER2 amplified breast cancer), development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab)\\n--------\\nImplies(B, D)\\nImplies(prognosis for HER2+ breast cancer patients has dramatically improved, patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(D), E)\\nImplies(Not(patient has HER2 amplified breast cancer), patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), A)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab)\\n--------\\nImplies(A, D)\\nImplies(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab, patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(B), C)\\nImplies(Not(prognosis for HER2+ breast cancer patients has dramatically improved), patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(Not(A), E)\\nImplies(Not(development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab), patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(C), E)\\nImplies(Not(patient has V777L HER2 mutated breast cancer), patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(B), D)\\nImplies(Not(prognosis for HER2+ breast cancer patients has dramatically improved), patient has HER2 amplified breast cancer)\\n--------\\nImplies(E, C)\\nImplies(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab, patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(D, C)\\nImplies(patient has HER2 amplified breast cancer, patient has V777L HER2 mutated breast cancer)\\n--------\\nImplies(C, E)\\nImplies(patient has V777L HER2 mutated breast cancer, patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(E), A)\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), development of a humanized monoclonal antibody that targets the HER2 receptor, trastuzumab)\\n--------\\nImplies(E, D)\\nImplies(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab, patient has HER2 amplified breast cancer)\\n--------\\nImplies(Not(E), E)\\nImplies(Not(patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab), patients with HER2 amplified breast cancer may benefit from treatment with Trastuzumab)\\n--------\\nImplies(Not(D), C)\\nImplies(Not(patient has HER2 amplified breast cancer), patient has V777L HER2 mutated breast cancer)\\n--------\\n'}"
        ]
    }
}